Publications by authors named "Adrienne D Cox"

Claim this Profile
C
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.
Szu-Aun Long, Haley Todd, Grace Goodhart, Wen-Hsuan Chang, Amber M Amparo, Adrienne D Cox

Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.
Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, Clint A Stalnecker, Addison G Stamey, Adrienne D Cox

Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.
Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, Kristina Drizyte-Miller, Jennifer E Klomp, Adrienne D Cox

Sci Signal· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS: the Achilles' heel of pancreas cancer biology.
Kristina Drizyte-Miller, Taiwo Talabi, Ashwin Somasundaram, Adrienne D Cox, Channing J Der

J Clin Invest· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer.
Jonathan M DeLiberty, Mallory K Roach, Clint A Stalnecker, Ryan Robb, Elyse G Schechter, Adrienne D Cox

Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugging mutant KRAS by disrupting binding to effectors and GTP.
Adrienne D Cox, Channing J Der

Nat Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Undruggable KRAS": druggable after all.
Adrienne D Cox, Channing J Der

Genes Dev· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS takes the road to destruction.
Adrienne D Cox, Channing J Der

Science· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.
Jennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, A Cole Edwards, Runying Yang, Adrienne D Cox

Science· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
Jeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, Kirsten L Bryant, A Cole Edwards, Adrienne D Cox

Science· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
A Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, Khalilah E Taylor, Jennifer E Klomp, Adrienne D Cox

Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RHOA drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling.
Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, Adrienne D Cox

Sci Signal· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in -mutant pancreatic cancer.
Ye S Lee, Jennifer E Klomp, Clint A Stalnecker, Craig M Goodwin, Yanzhe Gao, Adrienne D Cox

Genes Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Craig M Goodwin, Andrew M Waters, Jennifer E Klomp, Sehrish Javaid, Kirsten L Bryant, Adrienne D Cox

Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers.
Adrienne D Cox, Jenny P-Y Ting, Channing J Der

Cancer Discov· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional and biological heterogeneity of KRAS mutations.
Minh V Huynh, G Aaron Hobbs, Antje Schaefer, Mariaelena Pierobon, Leiah M Carey, Adrienne D Cox

Sci Signal· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
Sehrish Javaid, Antje Schaefer, Craig M Goodwin, Victoria V Nguyen, Frances L Massey, Adrienne D Cox

Mol Cancer Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
J Nathaniel Diehl, Priya S Hibshman, Irem Ozkan-Dagliyan, Craig M Goodwin, Sarah V Howard, Adrienne D Cox

Adv Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Clint A Stalnecker, Kajal R Grover, A Cole Edwards, Michael F Coleman, Runying Yang, Adrienne D Cox

Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth.
Danielle R Cook, Melissa Kang, Timothy D Martin, Joseph A Galanko, Gabriela H Loeza, Adrienne D Cox

Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
J Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, Priya S Hibshman, Devon R Blake, Adrienne D Cox

J Biol Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Jennifer E Klomp, Ye S Lee, Craig M Goodwin, Björn Papke, Jeff A Klomp, Adrienne D Cox

Cell Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filling in the GAPs in understanding RAS.
Adrienne D Cox, Channing J Der

Science· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering threshold-based selection systems.
Katherine H Pedone, Vanessa González-Pérez, Luciana E Leopold, Neal R Rasmussen, Channing J Der, Adrienne D Cox

G3 (Bethesda)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
Andrew M Waters, Tala O Khatib, Bjoern Papke, Craig M Goodwin, G Aaron Hobbs, Adrienne D Cox

Cell Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis